Targeting B-lymphocyte stimulator (BLyS) in immune-based rheumatic diseases: A therapeutic promise waiting to be fulfilled

Contemporary Targeted Therapies in Rheumatology

Volumn , Issue , 2007, Pages 527-542

  Stohl, William ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 60849102000     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (148)

1. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-3.
2. Shu H-B, Hu W-H, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 1999; 65: 680-3.
3. Schneider P, MacKay F, Steiner V et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747-56.
4. 2-terminal kinase. J Biol Chem 1999; 274: 15978-81.
5. Tribouley C, Wallroth M, Chan V et al. Characterization of a new member of the TNF family expressed on antigen presenting cells. Biol Chem 1999; 380: 1443-7.
6. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-9.
7. Nardelli B, Belvedere O, Roschke V et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97: 198-204.
8. Kanakaraj P, Migone T-S, Nardelli B et al. BLyS binds to B cells with high affinity and induces activation of the transcription factors NF-kB and ELF-1. Cytokine 2001; 13: 25-31.
9. Liu Y, Xu L, Opalka N et al. Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell 2002; 108: 383-94.
10. Kim HM, Yu KS, Lee ME et al. Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation. Nat Struct Biol 2003; 10: 342-8.
11. Liu Y, Hong X, Kappler J et al. Ligand-receptor binding revealed by the TNF family member TALL-1. Nature 2003; 423: 49-56.
12. Karpusas M, Cachero TG, Qian F et al. Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J Mol Biol 2002; 315: 1145-54.
13. Oren DA, Li Y, Volovik Y et al. Structural basis of BLyS receptor recognition. Nat Struct Biol 2002; 9: 288-92.
14. Zhukovsky EA, Lee J-O, Villegas M, Chan C, Chu S, Mroske C. Is TALL-1 a trimer of a virus-like cluster?Nature 2004; 427: 413-14.
15. Cachero TG, Schwartz IM, Qian F et al. Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF (B cell activating factor). Biochemistry 2006; 45: 2006-13.
16. Gavin AL, Aït-Azzouzene D, Ware CF, Nemazee D. ABAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem 2003; 278: 38220-8.
17. Gavin AL, Duong B, Skog P et al. ABAFF, a splice isoform of BAFF, opposes full length BAFF activity in vivo in transgenic mouse models. J Immunol 2005; 175: 319-28.
18. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002; 3: 424-9.
19. Novak AJ, Grote DM, Ziesmer SC et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006; 6: 983-7.
20. Scapini P, Nardelli B, Nadali G et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003; 197: 297-302.
21. Gorelik L, Gilbride K, Dobles M et al. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 2003; 198: 937-45.
22. Litinskiy MB, Nardelli B, Hilbert DM et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol2002; 3: 822-9.
23. He B, Qiao X, Klasse PJ et al. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 2006; 176: 3931-41.
24. Yoshimoto K, Takahashi Y, Ogasawara M et al.Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line, Loucy. Int Immunol 2006; 18: 1189-96.
25. He B, Chadburn A, Jou E et al. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004; 172: 3268-79.
26. Lin-Lee Y-C, Pham LV, Tamayo AT et al. Nuclear localization in the biology of the CD40 receptor in normal and neoplastic human B lymphocytes. J Biol Chem2006; 281: 18878-87.
27. Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: A mechanism for survival. Blood 2002; 100: 2973-9.
28. Novak AJ, Darce JR, Arendt BK et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival. Blood 2004; 103: 689-94.
29. Novak AJ, Grote DM, Stenson M et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004; 104: 2247-53.
30. Elsawa SF, Novak AJ, Grote DM et al. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenström macroglobulinemia. Blood 2006; 107: 2882-8.
31. Krumbholz M, Theil D, Derfuss T et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005; 201: 195-200.
32. Tschen S-I, Stohlman SA, Ramakrishna C et al. CNS viral infection diverts homing of antibody-secreting cells from lymphoid organs to the CNS. Eur J Immunol 2006; 36: 603-12.
33. Ohata J, Zvaifler NJ, Nishio M et al. Fibroblast-like synoviocytes of mesenchymal orgin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005; 174: 864-70.
34. Goodyear CS, Boyle DL, Silverman GJ. Secretion of BAFF by fibroblast-like synoviocytes from rheumatoid arthritis biopsies attenuates B-cell depletion by ritux-imab. Arthritis Rheum 2005; 52: S290.
35. Moon E-Y, Lee J-H, Oh S-Y et al. Reactive oxygen species augment B-cell-activating factor expression. Free Radic Biol Med 2006; 40: 2103-11.
36. Laabi Y, Gras M-P, Brouet J-C et al. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res1994; 22: 1147-54.
37. von Bülow G-U, Bram RJ. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997; 278: 138-41.
38. Thompson JS, Bixler SA, Qian F et al. BAFF-R, a novel TNF receptor that specifically interacts with BAFF. Science 2001; 293: 2108-11.
39. Yan M, Brady JR, Chan B et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol2001; 11: 1547-52.
40. Xia X-Z, Treanor J, Senaldi G et al. TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med2000; 192: 137-43.
41. Underhill GH, George D, Bremer EG, Kansas GS. Gene expression profiling reveals a highly specialized genetic program of plasma cells. Blood 2003; 101: 4013-21.
42. Tarte K, Zhan F, De Vos J, Klein B, Shaughnessy J Jr. Gene expression profiling of plasma cells and plasmablasts: Toward a better understanding of the late stages of B-cell differentiation. Blood 2003; 102: 592-600.
43. Avery DT, Kalled SL, Ellyard JI et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003; 112: 286-97.
44. O'Connor BP, Raman VS, Erickson LD et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004; 199: 91-7.
45. Shu H-B, Johnson H. B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. Proc Natl Acad Sci U S A 2000; 97: 9156-61.
46. Hatzoglou A, Roussel J, Bourgeade M-F et al. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kB, Elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol 2000; 165: 1322-30.
47. Xu L-G, Shu H-B. TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kB activation and IL-10 production. J Immunol 2002; 169: 6883-9.
48. Hikida M, Johmura S, Hashimoto A, Takezaki M, Kurosaki T. Coupling between B cell receptor and phospholipase C-y2 is essential for mature B cell development. J Exp Med 2003; 198: 581-9.
49. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NK-kB2 in maturing B cells. Nat Immunol 2002; 3: 958-65.
50. Kayagaki N, Yan M, Seshasayee D et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kB2. Immunity 2002; 10: 515-24.
51. Hatada EN, Do RKG, Orlofsky A et al. NF-kB1 p50 is required for BLyS attentuation of apoptosis but dispen-sible for processing of NF-kB2 p100 to p52 in quiescent mature B cells. J Immunol 2003; 171: 761-8.
52. Herrin BR, Justement LB. Expression of the adaptor protein hematopoietic Src homology 2 is up-regulated in response to stimuli that promote survival and differentiation of B cells. J Immunol 2006; 176: 4163-72.
53. Mecklenbräuker I, Kalled SL, Leitges M, Mackay F, Tarakhovsky A. Regulation of B-cell survival by BAFF-dependent PKCS-mediated nuclear signalling. Nature2004; 431: 456-61.
54. Hase H, Kanno Y, Kojima M et al. BAFF/BLyS can potentiate B-cell selection with the B-cell co-receptor complex. Blood 2004; 103: 2257-65.
55. d'Arbonneau F, Pers J-O, Devauchelle V et al. BAFF-induced changes in B cell antigen receptor-containing lipid rafts in Sjögren's syndrome. Arthritis Rheum 2006; 54: 115-26.
56. Thompson JS, Schneider P, Kalled SL et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med 2000; 192: 129-35.
57. Do RKG, Hatada E, Lee H et al. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000; 192: 953-64.
58. Batten M, Groom J, Cachero TG et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000; 192: 1453-65.
59. Harless SM, Lentz VM, Sah AP et al. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr Biol 2001; 11: 1986-9.
60. Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002; 168: 5993-6.
61. Mongini PKA, Inman JK, Han H et al. APRIL and BAFF promote increased viability of replicating human B2 cells via mechanism involving cyclooxygenase 2. J Immunol 2006; 176: 6736-51.
62. Craxton A, Draves KE, Gruppi A, Clark EA. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med2005; 202: 1363-74.
63. Oliver PM, Vass T, Kappler J, Marrack P. Loss of the proapoptotic protein, Bim, breaks B cell anergy. J Exp Med 2006; 203: 731-41.
64. Lgene expression restored splenic B lymphocyte development in BAFF-R mutant mice. J Immunol 2003; 170: 4593-600.
65. Sasaki Y, Derudder E, Hobeika E et al. Canonical NF-kB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity 2006; 24: 729-39.
66. Rolink AG, Tschopp J, Schneider P, Melchers F. BAFF is a survival and maturation factor for mouse B cells. Eur J Immunol 2002; 32: 2004-10.
67. Tardivel A, Tinel A, Lens S et al. The anti-apoptotic factor Bcl-2 can functionally substitute for the B cell survival but not for the marginal zone B cell differentiation activity of BAFF. Eur J Immunol 2004; 34: 509-18.
68. Yamada T, Zhang K, Yamada A, Zhu D, Saxon A. B lymphocyte stimulator activates p38 mitogen-activated protein kinase in human Ig class switch recombination. Am J Respir Cell Mol Biol 2005; 32: 388-94.
69. Castigli E, Wilson SA, Scott S et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 2005; 201: 35-9.
70. Ng LG, Ng C-H, Woehl B et al. BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur J Immunol2006; 36: 1837-46.
71. Miller JP, Stadanlick JE, Cancro MP. Space, selection, and surveillance: setting boundaries with BLyS. J Immunol 2006; 176: 6405-10.
72. Mackay F, Woodcock SA, Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697-710.
73. Khare SD, Sarosi I, Xia X-Z et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A 2000; 97: 3370-5.
74. Aït-Azzouzene D, Gavin AL, Skog P, Duong B, Nemazee D. Effect of cell: cell competition and BAFF expression on peripheral B cell tolerance and B-1 cell survival in transgenic mice expressing a low level of IgK-reactive macroself antigen. Eur J Immunol 2006; 36: 985-96.
75. Morel L, Rudofsky UH, Longmate JA, Schiffenbauer J, Wakeland EK. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1994; 1: 219-29.
76. Rozzo SJ, Allard JD, Choubey D et al. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 2001; 15: 435-43.
77. Morel L, Mohan C, Yu Y et al. Functional dissection of systemic lupus erythematosus using congenic mouse strains. J Immunol 1997; 158: 6019-28.
78. Mohan C, Alas E, Morel L, Yang P, Wakeland EK. Genetic dissection of SLE pathogenesis: Slel on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. J Clin Invest 1998; 101: 1362-72.
79. Stohl W, Xu D, Kim KS et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2080-91.
80. Groom J, Kalled SL, Cutler AH et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002; 109: 59-68.
81. Zhang M, Ko K-H, Lam QLK et al. Expression and function of TNF family member B cell-activating factor in the development of autoimmune arthritis. Int Immunol2005; 17: 1081-92.
82. Gross JA, Dillon SR, Mudri S et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15: 289-302.
83. Schiemann B, Gommerman JL, Vora K et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293: 2111-14.
84. Xu S, Lam D-P. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensible for humoral immune responses. Mol Cell Biol 2001; 21: 4067-74.
85. Yang M, Hase H, Legarda-Addison D et al. BCMA, the receptor for APRIL and BAFF, induces antigen presentation in B cells. J Immunol 2005; 175: 2814-24.
86. Shlomchik MJ, Madaio MP, Ni D, Trounstein M, Huszar D. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994; 180: 1295-306.
87. Chan O, Shlomchik MJ. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 1998; 160: 51-9.
88. Chan OTM, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189: 1639-47.
89. von Bülow G-U, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity 2001; 14: 573-82.
90. Yan M, Wang H, Chan B et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol2001; 2: 638-43.
91. Seshasayee D, Valdez P, Yan M et al. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003; 18: 279-88.
92. Salzer U, Chapel HM, Webster ADB et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005; 37: 820-8.
93. Castigli E, Wilson SA, Garibyan L et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005; 37: 829-34.
94. Sasaki Y, Casola S, Kutok JL, Rajewski K, Schmidt-Supprian M. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol 2004; 173: 2245-52.
95. Shulga-Morskaya S, Dobles M, Walsh ME et al. B cellactivating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 2004; 173: 2331-41.
96. Gorelik L, Cutler AH, Thill G et al. Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J Immunol 2004; 172: 762-6.
97. Lesley R, Xu Y, Kalled SL et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20: 441-53.
98. Thien M, Phan TG, Gardam S et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20: 785-98.
99. Jacob CO, Pricop L, Putterman C et al. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand Mixed 2328 mice deficient in BAFF. J Immunol 2006; 177: 2671-80.
100. Ramanujam M, Wang X, Huang W et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004; 173: 3524-34.
101. Ramanujam M, Wang X, Huang W et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006; 116: 724-34.
102. Wang H, Marsters SA, Baker T et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2001; 2: 632-7.
103. Gilbert JA, Kalled SL, Moorhead H et al. Treatment of autoimmune hyperthyroidism in a murine model of Graves' disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology. Endocrinology 2006; 147: 4561-8.
104. Hahne M, Kataoka T, Schröter M et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998; 188: 1185-90.
105. Kelly K, Manos E, Jensen G, Nadauld L, Jones DA. APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res 2000; 60: 1021-7.
106. Marsters SA, Yan M, Pitti RM et al. Interaction of the TNF homologues BLyS and APRIL with the receptor homologues BCMA and TACI. Curr Biol 2000; 10: 785-8.
107. Yu G, Boone T, Delaney J et al. APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 2000; 1: 252-6.
108. Wu Y, Bressette D, Carrell JA et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 2000; 275: 35478-85.
109. Rennert P, Schneider P, Cachero TG et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med 2000; 192: 1677-83.
110. Craxton A, Magaletti D, Ryan EJ, Clark EA. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 2003; 101: 4464-71.
111. Hendriks J, Planelles L, de Jong-Odding J et al.Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 2005; 12: 637-48.
112. Ingold K, Zumsteg A Tardivel A et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005; 201: 1375-83.
113. Varfolomeev E, Kischkel F, Martin F et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol 2004; 24: 997-1006.
114. Castigli E, Scott S, Dedeoglu F et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A 2004; 101: 3903-8.
115. Stein JV, López-Fraga M, Elustondo FA et al. APRIL modulates B and T cell immunity. J Clin Invest 2002; 109: 1587-98.
116. Roschke V, Sosnovtseva S, Ward CD et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002; 169: 4314-21.
117. Bischof D, Elsawa SF, Mantchev G et al. Selective activation of TACI by syndecan-2. Blood 2006; 107: 3235-42.
118. Stohl W, Metyas S, Tan S-M et al. Inverse association between circulating APRIL levels and serologic and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004; 63: 1096-103.
119. Zhang J, Roschke V, Baker KP et al. Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10.
120. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-19.
121. Stohl W, Metyas S, Tan S-M et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475-86.
122. Petri M, Stohl W, Chatham W et al. Association of BLyS™ with measures of disease activity in a prospective SLE observational study. Arthritis Rheum 2004; 50: S603.
123. Collins CE, Gavin AL, Migone T-S et al. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: Disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006; 8: R6.
124. Davis JC Jr, Gross J, Gescuk B, Harder B, Wofsy D. zTNF4 and soluble TACI receptor levels in serum and urine may reflect disease activity in patients with SLE. Arthritis Rheum 2001; 44: S99.
125. Carter RH, Zhao H, Liu X et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 3943-54.
126. Cambridge G, Stohl W, Leandro MJ et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006; 54: 723-32.
127. Tan S-M, Xu D, Roschke V et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003; 48: 982-92.
128. Seyler TM, Park YW, Takemura S et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005; 115: 3083-92.
129. Mariette X, Roux S, Zhang J et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003; 62: 168-71.
130. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J Clin Immunol 2005; 25: 189-201.
131. Pers J-O, Daridon C, Devauchelle V et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci2005; 1050: 34-9.
132. Pers J-O, d'Arbonneau F, Devauchelle-Pensec V et al.Is periodontal disease mediated by salivary BAFF in Sjögren's syndrome? Arthritis Rheum 2005; 52: 2411-14.
133. Szodoray P, Jellestad S, Teague MO, Jonsson R. Attenuated apoptosis of B cell activating factorexpressing cells in primary Sjögren's syndrome. Lab Invest 2003; 83: 357-65.
134. Lavie F, Miceli-Richard C, Quillard J et al. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome. J Pathol 2004; 202: 496-502.
135. Ittah M, Miceli-Richard C, Gottenberg J-E et al. B cellactivating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res Ther 2006; 8: R51.
136. Daridon C, Pers J-O, Devauchelle V et al. Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum2006; 54: 2280-8.
137. Matsushita T, Hasegawa M, Yanaba K et al. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006; 54: 192-201.
138. Krumbholz M, Specks U, Wick M et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 2005; 25: 298-302.
139. Sanders JS, Huitma MG, Kallenberg CGM, Stegeman CA. Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10, and B cell activator of the tumor necrosis factor family during follow-up in vasculitis associated with proteinase-3-antineutrophil cytoplasmic antibodies: Associations with disease activity and relapse. Ann Rheum Dis 2006; 65: 1484-9.
140. Baker KP, Edwards BM, Main SH et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003; 48: 3253-65.
141. Furie R, Stohl W, Ginzler E et al. Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of Lymphostat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum 2003; 48: S377.
142. McKay J, Chwalinska-Sadowska H, Boling E et al.Belimumab (BmAb), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population. Arthritis Rheum 2005; 52: S710-S711.
143. Stohl W, Chatham W, Weisman M et al. Belimumab (BmAb), a novel fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), selectively modulates B-cell sub-populations and immunoglobulins in a heterogeneous rheumatoid arthritis subject population. Arthritis Rheum 2005; 52: S444.
144. Emery P, Fleischmann RM, Filipowicz-Sosnowska A et al. Rituximab in rheumatoid arthritis: A doubleblind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2005; 52: S709.
145. Wallace DJ, Lisse J, Stohl W et al. Belimumab (BMAB), a fully human monoclonal antibody to B-lymphocyte stimulator (BLYS), shows bioactivity and reduces systemic lupus erythematosus disease activity. EULAR Abstracts Online 2006.
146. Gong Q, Ou Q, Ye S et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817-26.
147. Stohl W, Cheema GS, Briggs W et al. B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients. Clin Immunol 2002; 104: 115-22.
148. Rodriguez B, Valdez H, Freimuth W et al. Plasma levels of B-lymphocyte stimulator increase with HIV disease progression. AIDS 2003; 17: 1983-5.